Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds Vivasrespiratory-sleep-and-airway

Paeds Vivas · respiratory-sleep-and-airway

Narcolepsy and hypersomnolence — branching viva

Branching viva from a school-aged child with new excessive daytime sleepiness and emotion-triggered loss of muscle tone, through the recognition of cataplexy and narcolepsy type 1, the mechanism of orexin neuron loss, the confirmatory polysomnography, multiple sleep latency test and cerebrospinal fluid orexin, the layered management of sleepiness and cataplexy, and a pivot to an adolescent with sleepiness but no cataplexy in whom secondary and idiopathic hypersomnolence must be excluded.

branching clinical structured oral
On this page & tools

Target exams

RACP General PaediatricsRACP DCEMRCPCH ClinicalRCPSC Pediatrics

Target exams

RACP General PaediatricsRACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
You are the paediatric registrar in a general and sleep clinic. The examiner asks you to work through a ten-year-old with three months of irresistible daytime sleepiness who loses muscle tone in the head and knees when he laughs, and later an adolescent with excessive daytime sleepiness but no cataplexy. Information is released in stages.

Opening — framing the problem

The examiner begins: a ten-year-old has three months of irresistible daytime sleepiness and, when he laughs hard, his knees buckle and his head drops while he stays fully aware. Talk me through your reasoning. [1] [2]

I would frame this as narcolepsy type 1 until proven otherwise, because the pairing of new, irresistible daytime sleepiness with emotion-triggered loss of muscle tone and preserved consciousness is the clinical signature of cataplexy, which is nearly specific for narcolepsy type 1. The rapid weight gain points to the hypothalamic involvement seen in paediatric narcolepsy. [2] [7]

Branch A — the mechanism

Why does he lose muscle tone when he laughs, and what is the underlying lesion? [4]

Cataplexy is the muscle atonia of REM sleep released into wakefulness by strong emotion. The underlying lesion is loss of the orexin, or hypocretin, neurons in the lateral hypothalamus, which normally stabilise wakefulness and hold REM sleep in place; without orexin, the boundary between wake and REM breaks down, producing sleepiness, cataplexy, sleep paralysis and hypnagogic hallucinations. The loss is thought to be autoimmune on an HLA-DQB1*06:02 background. [4] [6]

Branch B — confirming the diagnosis

How would you confirm this, and what would you expect to find? [3]

I would arrange overnight polysomnography to exclude another cause and confirm adequate sleep, followed by a multiple sleep latency test the next day, expecting a mean sleep latency at or below eight minutes and two or more sleep-onset REM periods. Where the picture is doubtful, a low cerebrospinal fluid orexin level, at or below 110 picograms per millilitre, confirms narcolepsy type 1. I would ensure he is off REM-suppressing drugs first and interpret the numbers against his age. [3] [10]

Branch C — management

The diagnosis is confirmed. How will you treat him? [1]

I would start with the non-drug foundation of sleep hygiene and planned short daytime naps, plus school accommodations, safety advice and psychological support. For the sleepiness I would use a wake-promoting agent such as modafinil first line, with pitolisant, methylphenidate or solriamfetol as alternatives. For the cataplexy I would use sodium oxybate, which also improves sleepiness and night sleep, or a REM-suppressing antidepressant such as venlafaxine, tapering rather than stopping it abruptly. [12] [13]

Branch D — the pivot without cataplexy

Now an adolescent presents with excessive daytime sleepiness but no cataplexy at all. Does that change things? [1]

Without cataplexy I cannot assume narcolepsy type 1, and I must widen the differential to narcolepsy type 2, idiopathic hypersomnia and, most importantly, secondary sleepiness from insufficient sleep, obstructive sleep apnoea, delayed sleep phase, medication or depression. I would exclude these first, then use polysomnography and the multiple sleep latency test, remembering that type 2 is a diagnosis of exclusion that must be reviewed over time. [3] [1]

Closing — the safety rule

Give me the single safety point you would emphasise to this family. [9]

Cataplexy and severe sleepiness create injury risk, so I would advise supervision around water, roads and heights and, in due course, careful attention to driving; and I would warn never to stop an anticataplectic antidepressant abruptly, because sudden withdrawal can precipitate rebound cataplexy or status cataplecticus. [9] [3]

References

  1. [1]Morse AM; Kim SY; Harris S; et al Narcolepsy: Beyond the Classic Pentad. CNS Drugs, 2025.PMID 40111737
  2. [2]Rocca FL; Pizza F; Ricci E; et al Narcolepsy during Childhood: An Update. Neuropediatrics, 2015.PMID 25961600
  3. [3]Barateau L; Pizza F; Chenini S; et al Narcolepsies, update in 2023. Rev Neurol (Paris), 2023.PMID 37634997
  4. [4]Rauf R; Asif S; AlSaafeen A; et al Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers. Brain Behav, 2025.PMID 41076550
  5. [5]Vassalli A; Tafti M; Liblau RS Narcolepsy is (not) an autoimmune disease. Nat Rev Neurol, 2026.PMID 42321519
  6. [6]Ding WT; Gao JY; Guo ZL; et al Research Progress in the Roles of Influenza A H1N1 Virus and Its Vaccine in the Pathogenesis of Narcolepsy Type 1. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2025.PMID 41503654
  7. [7]Poli F; Pizza F; Mignot E; et al High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep, 2013.PMID 23372264
  8. [8]Dhanju S; Al-Saleh S; Amin R; et al A retrospective analysis of clinical characteristics of childhood narcolepsy. Paediatr Child Health, 2018.PMID 30455579
  9. [9]Pillen S; Pizza F; Dhondt K; et al Cataplexy and Its Mimics: Clinical Recognition and Management. Curr Treat Options Neurol, 2017.PMID 28478511
  10. [10]Biscarini F; Vandi S; Zenesini C; et al Use of Portable 24-Hour Polysomnography as Alternative Diagnostic Tool for Narcolepsy Type 1 in Adults and Children. Neurology, 2025.PMID 40080737
  11. [11]Tang SH; Min J; Zhang X; et al Incidence of pediatric narcolepsy diagnosis and management: evidence from claims data. J Clin Sleep Med, 2024.PMID 38450539
  12. [12]Keam SJ Pitolisant: Pediatric First Approval. Paediatr Drugs, 2023.PMID 37233887
  13. [13]Moresco M; Pizza F; Antelmi E; et al Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy. Curr Drug Metab, 2018.PMID 29512449
  14. [14]Dauvilliers Y; Lammers GJ; Lecendreux M; et al Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy. J Clin Sleep Med, 2024.PMID 37942930